Skip to main content

Drug Interaction Report

5 potential interactions and/or warnings found for the following 3 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Major

indomethacin meloxicam

Applies to: indomethacin, meloxicam

GENERALLY AVOID: Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy. Patients with a prior history of peptic ulcer disease and/or GI bleeding have a greater than 10-fold increased risk of developing a GI bleed during NSAID use compared to patients without a history. Additional risk factors include old age, alcohol use, smoking, and poor general health status.

MANAGEMENT: Concomitant use of more than one NSAID at a time should generally be avoided. Some authorities consider the concomitant use of more than one NSAID at a time to be contraindicated due to the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions (AU,UK). Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.

References (17)
  1. (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
  2. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  3. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  4. (2006) "Product Information. Anaprox (naproxen)." Roche Laboratories
  5. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  6. (2001) "Product Information. Daypro (oxaprozin)." Searle
  7. (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
  8. (2006) "Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group
  9. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  10. Cerner Multum, Inc. "Australian Product Information."
  11. (2009) "Product Information. Cambia (diclofenac)." Kowa Pharmaceuticals America (formerly ProEthic)
  12. (2009) "Product Information. Caldolor (ibuprofen)." Cumberland Pharmaceuticals Inc
  13. (2010) "Product Information. VIMOVO (esomeprazole-naproxen)." Astra-Zeneca Pharmaceuticals
  14. (2011) "Product Information. Duexis (famotidine-ibuprofen)." Horizon Therapeutics USA Inc
  15. (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
  16. (2016) "Product Information. Etodolac ER (etodolac)." Taro Pharmaceuticals U.S.A. Inc
  17. (2016) "Product Information. Ketoprofen ER (ketoprofen)." Mylan Pharmaceuticals Inc

No other interactions were found between your selected drugs. However, this does not necessarily mean no other interactions exist. Always consult your healthcare provider.

Drug and food interactions

Moderate

allopurinol food

Applies to: allopurinol

ADJUST DOSING INTERVAL: The tolerability of allopurinol may be improved by giving it after a meal. Additionally, when the dose is greater than 300 mg, dividing the total daily dose into smaller doses administered more often may be appropriate to help minimize gastrointestinal irritation.

MONITOR: Concomitant use of allopurinol with central nervous system (CNS) depressants, including alcohol, may potentiate adverse effects such as somnolence and sedation.

MANAGEMENT: To improve tolerability, some manufacturers suggest administering allopurinol after a meal. Additionally, if the daily dose is greater than 300 mg, administering allopurinol in divided doses may help reduce gastrointestinal intolerance. Patients should also be counseled to avoid or limit consumption of alcohol and to avoid activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them.

References (4)
  1. (2024) "Product Information. Allopurinol (Sandoz) (allopurinol)." Sandoz Pty Ltd
  2. (2021) "Product Information. Zyloric (allopurinol)." Aspen Pharma Trading Ltd
  3. (2021) "Product Information. Zyloprim (allopurinol)." AA Pharma Inc, 248178
  4. (2024) "Product Information. Allopurinol (allopurinol)." Actavis U.S. (Purepac Pharmaceutical Company)
Moderate

indomethacin food

Applies to: indomethacin

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References (1)
  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Non-narcotic analgesics

Therapeutic duplication

The recommended maximum number of medicines in the 'non-narcotic analgesics' category to be taken concurrently is usually two. Your list includes three medicines belonging to the 'non-narcotic analgesics' category:

  • indomethacin
  • allopurinol
  • meloxicam

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

Duplication

Nonsteroidal anti-inflammatories

Therapeutic duplication

The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category:

  • indomethacin
  • meloxicam

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.